Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, ...

California, USA-based biotech Allakos saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

Investing.com -- Shares of Allakos Inc . (NASDAQ:ALLK) plummeted 76% after the biopharmaceutical company announced the discontinuation of its AK006 development due to the drug's lack of ...

Allakos Inc. announced that its phase 1 trial of AK006 for chronic spontaneous urticaria (CSU) did not show therapeutic efficacy, leading the company to discontinue its development. While AK006 ...

The California-based company estimates that restructuring activities to close AK006 development will cost around $34 million to $38 million, with a major portion of these payments paid over in the ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).

Investing.com -- Shares of Allakos Inc . (NASDAQ: ALLK) plummeted 76% after the biopharmaceutical company announced the discontinuation of its AK006 development due to the drug's lack of therapeutic ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.